What Happens When You Stop Taking Mounjaro: Side Effects Explained

The biggest myth first: stopping Mounjaro does not cause withdrawal in the clinical sense

Most people searching "side effects of stopping Mounjaro" expect a list of new symptoms triggered by the medicine's absence, like the sweating and restlessness associated with stopping certain antidepressants or steroids. That is not what the evidence shows. Tirzepatide is not physically addictive, and the NHS patient information for tirzepatide does not list discontinuation syndrome as a recognised effect.

What tirzepatide does is suppress appetite and slow gastric emptying through its dual action on GIP and GLP-1 receptors. When you stop, those receptors stop being activated. Hunger returns. For many people that happens within days of the final dose, which has a half-life of roughly five days. The body is not in crisis; it is simply back to its pre-treatment state, which, for people with obesity, often means the hormonal drivers of appetite that existed before treatment are active again.

Some people do report short-term nausea or digestive changes in the days after stopping, likely reflecting the gut adjusting back to normal motility rates. These are generally mild and settle quickly. If you want a fuller picture of what to expect, our dedicated page on the side effects when stopping Mounjaro covers the most commonly reported experiences and how long they tend to last. If you experience anything severe or persistent after your last dose, that is reason to speak to a clinician, not to dismiss it.

What does actually happen after stopping, and how quickly

The clearest documented effect of stopping tirzepatide is weight regain. SURMOUNT-4, an extension phase of the tirzepatide clinical programme, showed that participants who switched from tirzepatide to placebo regained a substantial portion of lost weight over the subsequent 52 weeks, roughly two-thirds of what had been lost on treatment. The NICE appraisal of tirzepatide (TA1026) acknowledges weight maintenance after stopping as an open question and a reason ongoing monitoring matters.

This is not a side effect in the usual sense. It is the natural consequence of removing a treatment that was actively managing a chronic condition. Obesity is a condition shaped by biology, and tirzepatide works precisely because it intervenes in that biology. Remove the intervention without replacing it with something equally effective and the biology reasserts itself.

Appetite returning briskly is the main practical experience. People who have been in treatment for several months often describe feeling genuinely hungry in a way they had forgotten. Energy intake tends to creep up. This is worth being prepared for, particularly if stopping is planned: a conversation with your prescriber about how to protect the progress you have made is time well spent. You can read more about the side effects of stopping tirzepatide, including what the research says about timelines and how to manage the transition, in a dedicated resource. You can read more detail on what to expect from Mounjaro side effects after stopping in a dedicated resource.

Specific symptoms people report, including hair loss and mood changes

Two symptoms come up frequently in searches: hair loss and low mood. Both are worth addressing honestly.

Hair shedding after significant weight loss (on any method) is a recognised phenomenon called telogen effluvium. Rapid reduction in calorie intake puts physical stress on the body; hair follicles respond by entering a resting phase, and shedding becomes noticeable two to four months later. It is temporary in most cases and not caused by tirzepatide specifically. Hair loss after stopping Mounjaro is covered in its own page if this is a concern for you.

Mood changes are less straightforward. Some people find that appetite suppression, weight loss, and improved health markers lift mood considerably; when treatment stops, those benefits may partially reverse. There is no established causal link between stopping tirzepatide and clinical depression, but individual experiences vary. If low mood is a concern, our team has a resource on Mounjaro and depression-related side effects and your GP should always be looped in. Similarly, some people notice looser stools in the first week or two after stopping; the page on diarrhoea after stopping Mounjaro covers what is typical and what is not.

When to get medical help, and how to report concerns

Most of what people experience when stopping Mounjaro is not a medical emergency. Increased hunger, mild digestive changes, some fatigue: these tend to resolve within a couple of weeks. But some symptoms demand prompt attention.

Seek medical help urgently if you experience severe stomach pain that radiates to your back (with or without vomiting) as this may indicate pancreatitis, which the MHRA specifically flagged in a January 2026 Drug Safety Update for GLP-1 medicines. Symptoms of gallbladder problems (intense upper-right abdominal pain, particularly after eating), signs of an allergic reaction, or significant dehydration from persistent vomiting or diarrhoea also require prompt care. Call 111 or your GP; call 999 if symptoms are severe.

If you are on Mounjaro for type 2 diabetes and stop without a plan in place, your blood sugar management will need urgent review. Do not stop without a prescriber's guidance in that situation.

Anyone can report a suspected side effect, whether during or after treatment, via the MHRA's Yellow Card scheme. Patient reports are genuinely useful to regulators and help build the post-market safety picture for newer medicines like tirzepatide, which still carries a Black Triangle designation.

Our prescribers discuss what to expect (both during and after treatment) as a standard part of the consultation at nume. If you are weighing whether tirzepatide is right for you, or how to plan any future stopping point responsibly, that conversation is the right place to start.